Amphastar reports Q2 2026 revenue growth to $183.9M with adjusted EPS of $0.91, driven by new product launches.

Amphastar Pharmaceuticals posted net revenues of $183.9 million for Q2 2026, up 5% from the previous year, with adjusted non-GAAP net income of $40.8 million or $0.91 per share. Growth was supported by new product launches like ipratropium bromide and increased sales in other pharmaceuticals, despite pricing pressures on key products like BAQSIMI and glucagon. The company also achieved a $100 million milestone payment to Eli Lilly for BAQSIMI sales. Amphastar continues advancing its pipeline with multiple generic and biosimilar candidates targeting large markets, positioning for sustained growth.